Intermittent Hypoxia 2: Cardiovascular and Metabolism
Status:
Terminated
Trial end date:
2017-03-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare cardiovascular physiological adaptation to
intermittent hypoxia (IH) of nonobese healthy subjects. The exposure will be two periods of
two weeks (IH versus exposure "placebo hypoxia"). The investigators will use pharmacological
tools, peripheral vasodilator (amlodipine) or specific blocker of angiotensin receptor
(valsartan) versus the taking of a placebo. The allocation of the tool and the exhibition
will be randomized (HI / placebo, valsartan / amlodipine). The outcome measures evaluated
concern the cardiovascular system, systemic inflammation and tissular and glucose metabolism.
The investigators assume an increase in arterial resistance during the intermittent hypoxia
compared to the control group, these being dependent on sympathetic tone.
The investigators hypothesize that the metabolic alterations that will be observed after
experimental simulation (IH and fragmentation of sleep for 15 consecutive nights) will be
less severe in the valsartan group than in the amlodipine group in comparison with the
placebo group.
A serum bank and a gene bank will be performed for the requirements of subsequent studies if
necessary.